Report a data issue, formatting problem, or request follow-up. Our team responds within one business day.
Be the first to review this report.
Frovatriptan Succinate Tablets are immediate-release, film-coated oral tablets containing frovatriptan as the succinate monohydrate salt for the acute treatment of migraine with or without aura in adults; they are not intended for prophylaxis. The clinical strength is standardized to 2.5 mg frovatriptan free base per tablet, achieved by 3.91 mg frovatriptan succinate (monohydrate) as the active pharmaceutical ingredient (API). The succinate salt is selected for robust crystallinity, aqueous processability, and control of polymorphism/hydrate state, enabling consistent compressibility and dissolution. Typical excipients in a well-engineered formulation are a diluent (e.g., lactose monohydrate or anhydrous lactose) to achieve tablet mass and API dispersion, a direct-compression filler (microcrystalline cellulose) for tablet strength, a superdisintegrant (sodium starch glycolate or croscarmellose sodium) to ensure rapid breakup, a glidant (colloidal silicon dioxide) to stabilize flow, and a lubricant (magnesium stearate) controlled at low levels to avoid hydrophobic slowdown of dissolution; the film coat is commonly hypromellose-based with a plasticizer and opacifier to improve swallowability, light protection, and handling. Mechanistically, frovatriptan is a high-affinity 5-hydroxytryptamine (serotonin) 1B/1D receptor agonist. Therapeutic benefit in migraine derives from three convergent actions within the trigeminovascular system: selective constriction of dilated extracerebral intracranial arteries via 5-HT1B activation, inhibition of neuropeptide (e.g., CGRP) release from trigeminal terminals via 5-HT1D activation, and suppression of nociceptive transmission in central trigeminal pathways. Frovatriptan exhibits minimal activity at non-target serotonergic subtypes and negligible affinity for adrenergic, dopaminergic, or histaminergic receptors at therapeutic exposures, contributing to a clean pharmacodynamic profile. A distinguishing clinical pharmacology feature is its long terminal half-life (on the order of a day), which underpins a lower 24-hour headache recurrence rate compared with shorter-acting triptans. Key pharmacokinetics after a single 2.5 mg oral dose are consistent and predictable: absorption is complete with peak plasma concentrations typically reached about 2–4 hours post-dose; absolute oral bioavailability is modest (roughly one-quarter), reflecting first-pass metabolism rather than poor permeability. Plasma protein binding is low (≈15%), and a notable blood-to-plasma partitioning (~2:1) indicates red-cell association that effectively expands distribution. Elimination is driven by hepatic oxidative metabolism predominantly through CYP1A2 to hydroxylated and N-dealkylated species with much lower 5-HT1B/1D affinity than parent; renal excretion contributes to clearance but is not the dominant route. Food does not meaningfully alter the extent of absorption; at most it may delay t_max slightly without clinical consequence. Sex-related exposure differences are observed (higher systemic exposure in females), but dose adjustment is not required in routine practice. Severe hepatic impairment can increase exposure and is a context for caution or avoidance; mild-to-moderate renal impairment has limited effect given the drug’s distribution and metabolic clearance characteristics. Clinical use is straightforward: 2.5 mg orally at onset of migraine; if needed, a second 2.5 mg may be taken after at least 2 hours, with a maximum of 7.5 mg in 24 hours. Frovatriptan is contraindicated in ischemic heart disease, coronary vasospasm (Prinzmetal angina), history of stroke/TIA, uncontrolled hypertension, and within 24 hours of ergot-type migraine medications or another triptan. Serotonergic co-medication (SSRIs/SNRIs, linezolid, etc.) warrants vigilance for serotonin-toxicity symptoms. Clinically relevant pharmacokinetic interactions primarily involve strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), which can raise exposure; conversely, potent CYP1A2 induction (e.g., heavy cigarette smoking) may reduce exposure and effect. As with all triptans, hemiplegic or basilar/brainstem migraine phenotypes are outside the labeled use. From a CMC and manufacturing standpoint, the API is obtained as the succinate monohydrate with a controlled polymorphic/hydrate form verified by XRPD and water content (Karl Fischer) release tests. A modern, impurity-conscious synthesis typically constructs the indole/tetrahydrocarbazine core, installs the dimethylsulfonamide and side-chain functionality under conditions that minimize formation of sulfonate esters or other potential mutagenic species, and then performs salt formation with stoichiometric succinic acid in an alcohol–water system. Tight control of residual solvents (per ICH Q3C), elemental impurities (Q3D), and genotoxic impurities (M7) is expected, with specification limits justified by toxicological assessment and process capability. Particle-size distribution (e.g., D90 in the low-to-mid tens of micrometers) is set to balance blend homogeneity with dissolution performance; excessive micronization is avoided to prevent cohesion and flow problems. Tablet manufacture uses either direct compression (preferred for simplicity and fewer moisture/heat stresses) or a low-shear wet-granulation step if the chosen excipient system needs granule strengthening. Critical process parameters are blend uniformity (assayed by stratified sampling and near-IR where available), lubricant blending time (kept minimal to avoid over-lubrication that can impair disintegration), compaction force (to meet hardness/friability targets without capping), and coat application weight gain (for mechanical integrity and appearance while preserving immediate release). A well-designed quality target product profile specifies rapid disintegration (<15 min) and rapid dissolution in acidic medium (e.g., ≥80% released within 30 min in 0.1 N HCl under paddle conditions), aligned with the reference product to support bioequivalence. Release testing covers identification (IR/UV and chromatographic), assay and content uniformity (HPLC), related substances (stability-indicating HPLC with qualified reporting/qualification thresholds), dissolution, water content, and microbial limits as appropriate for a non-sterile solid. Stability programs follow ICH climatic zone-appropriate conditions to set shelf life; packaging is moisture-protective (alu-alu blisters or HDPE bottles with desiccant), given the hydrate form’s sensitivity to low-humidity environments that can shift water content and subtly affect dissolution. Bioequivalence for generic products adheres to standard single-dose, crossover studies in healthy adults with fasting conditions, comparing C_max and AUC (0-t and 0-∞) within the conventional 80–125% confidence intervals; a supportive fed study may be required to bracket food effects depending on jurisdiction. Comparative dissolution across at least three media (acidic, intermediate pH, and buffer) and multiple paddle speeds is used as an in-vitro surrogate to ensure formulation sameness. In vitro–in vivo correlation is not typically established for immediate-release triptans, so dissolution method robustness and discriminatory power carry added weight in lifecycle controls. Risk management focuses on class-specific vascular events, medication-overuse headache with frequent use, and rare hypersensitivity. Patient-level good practice emphasizes using the earliest effective dose at attack onset, respecting 24-hour maxima, avoiding duplicate triptan/ergot therapy windows, and screening for cardiovascular disease before first use in at-risk populations. At the product level, a disciplined control strategy—from route design that avoids genotoxic liabilities through validated analytics and stability-indicating methods—ensures a reproducible, high-quality tablet whose clinical performance matches the reference while maintaining manufacturing robustness over the product lifecycle.
You may also be interested in
